Tandem Diabetes Care Inc TNDM
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNDM is a good fit for your portfolio.
News
-
Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024
-
Tandem Diabetes Care Prices Upsized Private Placement of $275.0 Million of Convertible Senior Notes Due 2029
-
Tandem Diabetes Care Shares Drop 12% After Private Placement for Senior Notes
-
Tandem Diabetes Care Announces Proposed Private Placement of Convertible Notes
-
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance
-
Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System
-
Tandem Diabetes Care Announces Upcoming Conference Presentations
-
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
Trading Information
- Previous Close Price
- $31.75
- Day Range
- $30.57–32.14
- 52-Week Range
- $13.82–41.92
- Bid/Ask
- $30.91 / $30.95
- Market Cap
- $2.00 Bil
- Volume/Avg
- 1.1 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.76
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tandem Diabetes Care Inc designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. Nearly three quarters of total revenue is derived from the U.S., with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,400
- Website
- https://www.tandemdiabetes.com
Competitors
Valuation
|
Metric
|
TNDM
|
PODD
|
DXCM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 61.13 | 90.46 |
Price/Book Value | 6.64 | 15.86 | 25.43 |
Price/Sales | 2.76 | 7.21 | 16.04 |
Price/Cash Flow | — | 36.40 | 77.94 |
Price/Earnings
TNDM
PODD
DXCM
Financial Strength
|
Metric
|
TNDM
|
PODD
|
DXCM
|
|---|---|---|---|
Quick Ratio | 2.94 | 2.36 | 2.39 |
Current Ratio | 3.83 | 3.51 | 2.84 |
Interest Coverage | −31.14 | 6.14 | 29.34 |
Quick Ratio
TNDM
PODD
DXCM
Profitability
|
Metric
|
TNDM
|
PODD
|
DXCM
|
|---|---|---|---|
Return on Assets (Normalized) | −10.52% | 8.02% | 10.03% |
Return on Equity (Normalized) | −29.38% | 33.45% | 28.40% |
Return on Invested Capital (Normalized) | −14.89% | 10.07% | 11.06% |
Return on Assets
TNDM
PODD
DXCM
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Yrxfdkmc | Hlxysm | $183.8 Bil | |
SYK
| Stryker Corp | Fdsdrlgsyp | Tymbj | $127.8 Bil | |
MDT
| Medtronic PLC | Hswzgxrm | Jvlmrm | $105.0 Bil | |
BSX
| Boston Scientific Corp | Phhhzjykd | Nhhmtd | $99.9 Bil | |
EW
| Edwards Lifesciences Corp | Hfsxjyynm | Cdncv | $52.5 Bil | |
DXCM
| DexCom Inc | Mbdswkkp | Dmj | $51.9 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Mdhtfwssp | Khzq | $24.9 Bil | |
ALGN
| Align Technology Inc | Rtnqyqgg | Nsqhsjd | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Krcdxlrv | Tgksk | $18.2 Bil | |
PODD
| Insulet Corp | Ntgsrjgt | Hzgnhn | $11.6 Bil |